1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
February 2023 in “Reactions Weekly”
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is a recommended first treatment for frontal fibrosing alopecia.
3 citations
,
May 2014 in “Journal of the Egyptian Women's Dermatologic Society /Journal of the Egyptian Women's Dermatologic Society” Bimatoprost may help treat hair loss from alopecia areata.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
3 citations
,
October 2018 in “Experimental and Therapeutic Medicine” Stopping tamsulosin one month before cataract surgery reduces eye surgery complications in rats.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
33 citations
,
January 2002 Latanoprost, a glaucoma drug, showed potential for promoting hair growth in bald monkeys, especially at higher doses.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
July 2022 in “British Journal of Dermatology” 1 citations
,
December 2024 in “Archives of Iranian Medicine” Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
7 citations
,
May 2018 in “Curēus” Bimatoprost 0.03% solution effectively promotes eyebrow growth.
5 citations
,
July 2019 in “Photodiagnosis and photodynamic therapy” Using tacalcitol ointment with photodynamic therapy may effectively treat follicular mucinosis with scalp hair loss.
3 citations
,
November 1998 in “PubMed” 114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” The new clobetasol propionate foam is effective and safe for treating alopecia areata.
Flutamide effectively treats female pattern hair loss long-term with low doses being safe for the liver.
July 2022 in “Dermatologic Therapy”
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
August 2017 in “Journal of the Dermatology Nurses' Association” Latisse (bimatoprost 0.03%) is widely used in dermatology but the document doesn't give detailed evidence or numbers.
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
98 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.